- Home
- AACG vs CUE Comparison
AACG vs CUE Comparison
Compare AACG & CUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AACG
- CUE
- Stock Information
- Founded
- AACG 1999
- CUE 2014
- Country
- AACG China
- CUE United States
- Employees
- AACG N/A
- CUE N/A
- Industry
- AACG Other Consumer Services
- CUE Biotechnology: Pharmaceutical Preparations
- Sector
- AACG Real Estate
- CUE Health Care
- Exchange
- AACG Nasdaq
- CUE Nasdaq
- Market Cap
- AACG 65.1M
- CUE 59.5M
- IPO Year
- AACG N/A
- CUE 2018
- Fundamental
- Price
- AACG $2.51
- CUE $0.73
- Analyst Decision
- AACG
- CUE Strong Buy
- Analyst Count
- AACG 0
- CUE 2
- Target Price
- AACG N/A
- CUE $3.00
- AVG Volume (30 Days)
- AACG 77.4K
- CUE 132.9K
- Earning Date
- AACG 11-06-2025
- CUE 11-13-2025
- Dividend Yield
- AACG N/A
- CUE N/A
- EPS Growth
- AACG N/A
- CUE N/A
- EPS
- AACG N/A
- CUE N/A
- Revenue
- AACG $39,064,701.00
- CUE $8,286,000.00
- Revenue This Year
- AACG N/A
- CUE N/A
- Revenue Next Year
- AACG N/A
- CUE $13.27
- P/E Ratio
- AACG N/A
- CUE N/A
- Revenue Growth
- AACG 15.19
- CUE N/A
- 52 Week Low
- AACG $0.50
- CUE $0.45
- 52 Week High
- AACG $2.58
- CUE $1.99
- Technical
- Relative Strength Index (RSI)
- AACG 66.97
- CUE 37.43
- Support Level
- AACG $2.05
- CUE $0.71
- Resistance Level
- AACG $2.58
- CUE $0.78
- Average True Range (ATR)
- AACG 0.20
- CUE 0.03
- MACD
- AACG 0.02
- CUE -0.01
- Stochastic Oscillator
- AACG 91.67
- CUE 20.10
About AACG ATA Creativity Global
ATA Creativity Global is an international educational services company focused on providing quality learning experiences that cultivate and enhance students' creativity. The operating segments of the company are (i) Overseas art study services (ii) Other educational services and (iii) Other services. Majority of its revenue comes from Overseas art study services.
About CUE Cue Biopharma Inc.
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others.